RT Journal Article
SR Electronic
T1 SARS-CoV-2 infections and antibody responses among health care workers in a Spanish hospital after a month of follow-up
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20180125
DO 10.1101/2020.08.23.20180125
A1 Gemma Moncunill
A1 Alfredo Mayor
A1 Rebeca Santano
A1 Alfons Jiménez
A1 Marta Vidal
A1 Marta Tortajada
A1 Sergi Sanz
A1 Susana Méndez
A1 Anna Llupià
A1 Ruth Aguilar
A1 Selena Alonso
A1 Diana Barrios
A1 Carlo Carolis
A1 Pau Cisteró
A1 Eugenia Chóliz
A1 Angeline Cruz
A1 Silvia Fochs
A1 Chenjerai Jairoce
A1 Jochen Hecht
A1 Montserrat Lamoglia
A1 Mikel J. Martínez
A1 Javier Moreno
A1 Robert A. Mitchell
A1 Natalia Ortega
A1 Nuria Pey
A1 Laura Puyol
A1 Marta Ribes
A1 Neus Rosell
A1 Patricia Sotomayor
A1 Sara Torres
A1 Sarah Williams
A1 Sonia Barroso
A1 Anna Vilella
A1 Antoni Trilla
A1 Pilar Varela
A1 Carlota Dobaño
A1 Alberto L Garcia-Basteiro
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180125.abstract
AB Background At the peak of the COVID-19 pandemic in Spain, cumulative prevalence of SARS-CoV-2 infection in a cohort of 578 randomly selected health care workers (HCW) from Hospital Clínic de Barcelona was 11.2%.Methods A follow-up survey one month after the baseline (April-May 2020) measured SARS-CoV-2 infection by real time reverse-transcriptase polymerase chain reaction (rRT-PCR) and IgM, IgA, IgG and subclasses to the receptor-binding domain of the SARS-CoV-2 spike protein by Luminex. Prevalence of infection was defined by a positive SARS-CoV-2 rRT-PCR and/or antibody seropositivity.Results The cumulative prevalence of infection at month 1 was 14.9% (84/565) and the seroprevalence 14.5% (82/565) for IgM and/or IgG and/or IgA. We found 25 (5%) new infections in participants without previous evidence of infection at baseline (501) and two participants seroreverted for IgM and/or IgG and/or IgA. Among seropositive participants at baseline, IgM and IgA levels generally declined at month 1 (antibody decay rates of 0.49 (95% CI, 0.40-0.60) and 0.34 (95% CI, 0.26-0.44)), respectively. Eight percent of the participants seroreverted for IgM and 11% for IgA. Subjects reporting COVID-19-like symptoms and laboratory and other technicians had higher risk of infection. The most frequent subclass responses were IgG1 and IgG2, followed by IgG3, with higher levels of IgG1, and only IgA1 but no IgA2 was detected.Conclusions Our findings highlight the importance of a continuous and improved surveillance of SARS-CoV-2 infections in HCW, particularly in high risk groups. The decay of IgA and IgM levels have implications for seroprevalence studies using these isotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInternal ISGlobal funds and in-kind contributions of HCB. GM had the support of the Department of Health, Catalan Government (SLT006/17/00109). Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. We acknowledge support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee at HCB (Ref number: HCB/2020/0336)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are provided in the manuscript and supplementary materials. Individual raw data are available upon request